MK 1248Alternative Names: MK1248
Latest Information Update: 17 Dec 2015
At a glance
- Originator Merck Sharp & Dohme
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Nov 2015 Phase-I clinical trials in Solid tumours (Monotherapy, Combination therapy, Late-stage disease) in Australia (IV)
- 16 Sep 2015 Merck Sharp & Dohme plans a phase I trial for Solid tumours in USA (NCT02553499)